PacBio

About PacBio

PacBio is a company focused on providing revolutionary sequencing technologies that combine the completeness of long reads with the accuracy of short reads to offer the most comprehensive view of genomes, transcriptomes, and epigenomes. Their mission is to advance research in genomics and related fields with high-accuracy sequencing solutions.

Products & Services

Sequencing Systems:Includes Revio long-read system, Vega long-read system, and Onso short-read system for various sequencing needs.

Technologies:Features HiFi long-read sequencing, SBB short-read sequencing, Kinnex, PureTarget, and Nanobind DNA extraction technologies.

Consumables:Offers sample prep kits, application kits, library prep and barcoding kits, HiFi sequencing kits, and Onso sequencing kits.

Sequencing Methods:Covers whole genome sequencing, targeted sequencing, RNA sequencing, single-cell RNA sequencing, epigenetics, and microbiome/metagenomics.

Software + Bioinformatics:Includes SMRT Link, computational tools, Onso software, and compatible partner software for data analysis.

Specialties

HiFi Long-Read Sequencing Short-Read Sequencing (SBB) Whole Genome Sequencing Targeted Sequencing RNA Sequencing Epigenetics Microbiome and Metagenomics Human Genomics Microbial Genomics Plant and Animal Genomics Cancer Genomics Biopharma Applications

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Debt T: - FT: Convertible Debt	A: 459000000 MR: - FA: $459 million FAN: 459000000	D: 2024-11-07 FD: 2024-11-07	1 investors
2	RT: Convertible Debt T: - FT: Convertible Debt	A: 441000000 MR: - FA: 441 million FAN: 441000000	D: 2023-06-26 FD: 2023-06-26	-
3	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: $150.0 million FAN: 150000000	D: 2023-01-24 FD: 2023-01-24	4 investors
4	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: approximately $175.0 million FAN: 175000000	D: 2023-01-24 FD: 2023-01-24	4 investors

Convertible Debt Latest

2024-11-07

$459.0M

1 investor (Pro only)

Convertible Debt 2023-06-26

$441.0M

Public Offering 2023-01-24

$150.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jay Shendure

Professor of Genome Sciences at University of Washington

E

Euan Ashley

Associate Dean and Professor of Medicine, School of Medicine, Roger and Joelle Burnell Professor of Genomics and Precision Health at Stanford University

O

Olga Troyanskaya

Professor in the Department of Computer Science and the Lewis-Sigler Institute for Integrative Genomics at Princeton University and the Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology

J

John F. Milligan

Chairman of the Board

C

Christian Henry

President & Chief Executive Officer

B

Bill Ericson

Founding Partner, Wildcat Venture Partners

View 14 more team members with Pro

Unlock Full Team Directory

Recent News

PacBio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised